A5068013727- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Retinal Imaging and Analysis
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Glaucoma and retinal disorders
- Hepatocellular Carcinoma Treatment and Prognosis
- Retinal Diseases and Treatments
- Cancer, Hypoxia, and Metabolism
- Liver physiology and pathology
- Cancer therapeutics and mechanisms
- Retinal and Macular Surgery
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Retinal and Optic Conditions
- Ocular Oncology and Treatments
- Systemic Sclerosis and Related Diseases
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Radiopharmaceutical Chemistry and Applications
- Uterine Myomas and Treatments
- Helminth infection and control
- Lymphoma Diagnosis and Treatment
National Defense Medical College
2024
Kanazawa University
2006-2020
Kanazawa University Hospital
2006-2020
Hiroshima University
2006-2010
Komatsu (Japan)
2004-2009
Kanazawa Medical Center
2009
AstraZeneca (United Kingdom)
2007
Abbott (United Kingdom)
2007
Kouseiren Takaoka Hospital
2006
Ishikawa Prefectural Central Hospital
2006
To investigate whether the aqueous levels of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) are correlated to vitreous these substances severity macular oedema in branch retinal vein occlusion (BRVO).Aqueous samples were obtained during cataract surgery from 24 patients (24 eyes) with BRVO. The VEGF IL-6 humour, fluid, plasma determined by enzyme-linked immunosorbent assay. degree ischaemia was evaluated terms area capillary nonperfusion using Scion Image. OCT.The level...
The aim of this study was to evaluate the usefulness EGFR mutation status in serum DNA as a means predicting benefit from gefitinib (IRESSA) therapy Japanese patients with non-small cell lung cancer (NSCLC). We obtained pairs tumour and samples 42 treated gefitinib. determined by direct sequencing method Scorpion Amplification Refractory Mutation System (ARMS) technology. mutations were detected eight seven patients. tumours consistent 39 (92.9%) pairs. strong correlations between both...
Epidermal growth factor receptor (EGFR) mutations are strong determinants of tumour response to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC). Pleural effusion is a common complication cancer. In this study, we assessed the feasibility detection samples pleural fluid. We obtained 43 samples, which was cell-free supernatant fluid, from Japanese NSCLC patients, and examined them for mutations. The epidermal mutation status determined by direct sequencing method (exons...
The relationship between the blood-flow velocity in perifoveal capillaries and macular oedema was investigated patients with branch retinal vein occlusion (BRVO).This study compared 18 BRVO 16 healthy volunteers. Perifoveal capillary measured on fluorescein angiograms a scanning laser ophthalmoscope by tracing method. Retinal thickness at central fovea optical coherence tomography. Then, relation investigated.Perifoveal significantly lower (1.08 (SD 0.28) mm/s) than volunteers (1.49 (0.11)...
7074 Background: Gefitinib is effective as a 2nd or 3rd line treatment for non-small cell lung cancer (NSCLC), but efficacy chemotherapy-naïve patients (pts) with NSCLC has not been established. Recently, EGFR gene mutation reported to be predictor of response gefitinib. Methods: We conducted phase II study evaluating the and safety gefitinib in NSCLC. The primary endpoint was rate (RR). also investigated whether the15-bp deletion (E746 A750del) could observed serum DNA served noninvasive...
<h3>BACKGROUND AND PURPOSE:</h3> Volumetry may be useful for evaluating treatment response and prognosis of intraocular lesions. Phantom, volunteer, patient studies were performed to determine whether ocular MR volumetry is reproducible. <h3>MATERIALS METHODS:</h3> Half-Fourier single-shot RARE FSPGR sequences at 1.5T with a 76-mm-diameter surface coil optimized obtain still images. accuracies each sequence compared simulated subretinal phantom volumes. Ocular was in 15 volunteers twice 1...
e18021 Background: Several studies have reported that increased gene copy number (GCN) of c-Met is associated with poor prognosis and resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI). A recent phase II study mostly Caucasian subjects showed addition a receptor TKI EGFR-TKI prolonged progression-free survival in NSCLC. It unclear whether status differs between Caucasians Asians. Thus, GCN was evaluated Japanese patients advanced NSCLC determine could be therapeutic target Asian...
Herein, we report a case of plasmablastic lymphoma (PBL) and diffuse large B-cell (DLBCL) that occurred concurrently in the intestine. An 84-year-old female presented with palpable rectal tumor ileocecal observed on imaging analyses. Endoscopic biopsy both lesions revealed lymphomatous round cells. Hartmann’s operation resection were performed for regional control. The lesion consisted proliferation CD20/CD79a-positive lymphoid cells, indicative DLBCL. In contrast, showed atypical cells...
8096 Background: Epidermal growth factor receptor (EGFR) mutations, amplification, and K-ras mutations are known as predictive of the EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy in patients (pts) with NSCLC. Prognostic influences those biomarkers remain matter to be discussed. Methods: Consecutive pts advanced NSCLC who were examined genotype received 1st line cytotoxic chemotherapy enrolled. amplification mutation analyzed if sufficient tumor samples available. Results: 87 enrolled...
7192 Background: Epidermal growth factor receptor (EGFR) gene amplification and mutation have been reported to be predictors of response EGFR inhibitors. We evaluated copy number mutations in biopsy samples non-small cell lung cancer (NSCLC) treated with gefitinib (G) analyzed the correlation between status clinical outcome. Methods: numbers were using FISH categorized as described by Cappuzzo et al. also performed mutational analysesof exons 18, 19 21 PCR direct sequencing. Response was...
7091 Background: Gefitinib (G) is an EGFR-TK inhibitors and G paclitaxel (P) have synergistic antitumor effect in G-resistant non-small cell lung cancer lines vitro. The purpose of this phase II trial was to evaluate the activity toxicity pts with G-refractory or NSCLC co-administration weekly P. Methods: Eligibilities were histologically cytologically proven resistant refractory cytotoxic chemotherapy, measurable lesion, ECOG PS0–2, adequate organ functions, life expectancy longer than 12...
7091 Background: Gefitinib (G) is an EGFR-TK inhibitors and G paclitaxel (P) have synergistic antitumor effect in G-resistant non-small cell lung cancer lines vitro. The purpose of this phase II trial was to evaluate the activity toxicity pts with G-refractory or NSCLC co-administration weekly P. Methods: Eligibilities were histologically cytologically proven resistant refractory cytotoxic chemotherapy, measurable lesion, ECOG PS0–2, adequate organ functions, life expectancy longer than 12...
10601 Background: The EGFR mutation status is a validated biomarker for the stratification of EGFR-tyrosine kinase inhibitor (EGFR-TKIs) treatment in patients with non-small-cell lung cancer (NSCLC); however, its use limited wild-type EGFR, and new biomarkers are needed. We hypothesized that serum concentration heparan sulfate (HS), which activates oncogenic growth factor receptor signaling through non-EGFR pathways, may be novel glycobiological EGFR-TKIs NSCLC. Methods: pre-treatment HS...
7563 Background: EGFR mutation status has emerged to be a validated predictive biomarker for the response EGFR-tyrosine kinase inhibitors (EGFR-TKI) treatment in non-small cell lung cancer. However, other biomarkers EGFR-TKI have not been identified. Methods: We retrospectively analyzed serum concentration of 13 molecules cohort 95 patients (pts) with adenocarcinoma who received from 3 centers. Pretreatment concentrations HGF, amphiregulin, Beta-cellulin, EGF, sEGFR, Epiregulin, FGF-basic,...
7599 Background: In the phase III Iressa (gefitinib) Survival Evaluation in Lung cancer (ISEL) trial, high epidermal growth factor receptor (EGFR) gene copy number was a predictor of gefitinib effect on survival patients (pts) with refractory advanced non-small-cell lung (NSCLC) (hazard ratio 0.61 vs 1.16 for low number; p=0.045) [JCO 2006;24:5034–42]. Although EGFR mutation status may predict response to Japanese pts, there is insufficient data clarify if assessed by fluorescence situ...
19007 Background: Although EGFR mutation is a strong predictive factor of EGFR-TKI, it difficult to obtain tumor tissue which suitable examine mutations in patients (pts) with metastatic non-small cell lung cancer (NSCLC). The objectives study are evaluate roles plasma and HER2 levels as biomarker gefitinib treatment. Methods: Patients: pts who histologically or cytologically proven NSCLC received 250 mg daily. Plasma were measured by ELISA kit (Oncogene Science, USA) manufacture’s...